Works matching AU HOMPESCH, MARCUS

Results: 48
    1
    2
    3
    4

    Exploring the insulin secretory properties of the PGD<sub>2</sub>-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.

    Published in:
    PLoS ONE, 2018, v. 13, n. 12, p. 1, doi. 10.1371/journal.pone.0208998
    By:
    • Skrtic, Stanko;
    • Tyrberg, Björn;
    • Broberg, Malin;
    • Ericsson, Hans;
    • Schnecke, Volker;
    • Kjaer, Magnus;
    • Hompesch, Marcus;
    • Andersson, Eva-Marie;
    • Ryberg, Erik;
    • Aivazidis, Alexander;
    • Wennberg Huldt, Charlotte;
    • Löfgren, Lars;
    • Morrow, Linda;
    • Parkinson, Joanna;
    • Rydén-Bergsten, Tina;
    • Watkins, Elaine;
    • Sörhede Winzell, Maria
    Publication type:
    Article
    5
    6
    7

    Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 700, doi. 10.1111/dom.14272
    By:
    • Beysen, Carine;
    • Schroeder, Patricia;
    • Wu, Eric;
    • Brevard, Julie;
    • Ribadeneira, Maria;
    • Lu, Wei;
    • Dole, Kiran;
    • O'Reilly, Terry;
    • Morrow, Linda;
    • Hompesch, Marcus;
    • Hellerstein, Marc K.;
    • Li, Kelvin;
    • Johansson, Lars;
    • Kelly, Patrick F.
    Publication type:
    Article
    8
    9
    10

    Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.

    Published in:
    Alimentary Pharmacology & Therapeutics, 2025, v. 61, n. 9, p. 1467, doi. 10.1111/apt.70020
    By:
    • Younossi, Zobair M.;
    • Razavi, Homie;
    • Sherman, Michael;
    • Allen, Alina M.;
    • Anstee, Quentin M.;
    • Cusi, Kenneth;
    • Friedman, Scott L.;
    • Lawitz, Eric;
    • Lazarus, Jeffrey V.;
    • Schuppan, Detlef;
    • Romero‐Gómez, Manuel;
    • Schattenberg, Jörn M.;
    • Vos, Miriam B.;
    • Wong, Vincent Wai‐Sun;
    • Ratziu, Vlad;
    • Hompesch, Marcus;
    • Sanyal, Arun J.;
    • Loomba, Rohit
    Publication type:
    Article
    11
    12

    Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action 每日1次给予德谷胰岛素(一种持续作用时间超长的基础胰岛素)治疗后在2-3日内可以达到稳态

    Published in:
    Journal of Diabetes, 2016, v. 8, n. 1, p. 132, doi. 10.1111/1753-0407.12266
    By:
    • Heise, Tim;
    • Korsatko, Stefan;
    • Nosek, Leszek;
    • Coester, Hans Veit;
    • Deller, Sigrid;
    • Roepstorff, Carsten;
    • Segel, Stine;
    • Kapur, Rahul;
    • Haahr, Hanne;
    • Hompesch, Marcus
    Publication type:
    Article
    13
    14

    First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.

    Published in:
    BMC Pharmacology & Toxicology, 2013, v. 14, n. 1, p. 1, doi. 10.1186/2050-6511-14-26
    By:
    • Kapur, Anita;
    • O'Connor-Semmes, Robin;
    • Hussey, Elizabeth K.;
    • Dobbins, Robert L.;
    • Wenli Tao;
    • Hompesch, Marcus;
    • Smith, Glenn A.;
    • Polli, Joseph W.;
    • James Jr., Charles D.;
    • Mikoshiba, Imao;
    • Nunez, Derek J.
    Publication type:
    Article
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45

    CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.

    Published in:
    Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01788-6
    By:
    • Schnell, Oliver;
    • Battelino, Tadej;
    • Bergenstal, Richard;
    • Birkenfeld, Andreas L.;
    • Ceriello, Antonio;
    • Cheng, Alice;
    • Davies, Melanie;
    • Edelman, Steve;
    • Forst, Thomas;
    • Giorgino, Francesco;
    • Green, Jennifer;
    • Groop, Per-Henrik;
    • Hadjadj, Samy;
    • J.L.Heerspink, Hiddo;
    • Hompesch, Marcus;
    • Izthak, Baruch;
    • Ji, Linong;
    • Kanumilli, Naresh;
    • Mankovsky, Boris;
    • Mathieu, Chantal
    Publication type:
    Article
    46

    Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 400, doi. 10.1111/dom.13084
    By:
    • Crutchlow, Michael F.;
    • Palcza, John S.;
    • Mostoller, Kate M.;
    • Mahon, Chantal D.;
    • Barbour, April M.;
    • Marcos, Michael C.;
    • Xu, Yang;
    • Watkins, Elaine;
    • Morrow, Linda;
    • Hompesch, Marcus
    Publication type:
    Article
    47
    48